SK Biopharm will participate in the 2026 BIO International Convention (BIO USA) to promote its global partnerships and artificial intelligence (AI)-based drug development strategies. The company plans to explore new collaboration opportunities and share its approach to utilizing AI across research and development (R&D).
The event will take place from June 22 to 25 at the San Diego Convention Center in the United States.
BIO USA, organized by the Biotechnology Innovation Organization, is the largest biotechnology event in the world. This year, over 20,000 industry professionals from 76 countries are expected to attend to share key industry trends and innovative technologies.
For the second consecutive year, SK Biopharm will operate a standalone booth in the major exhibition area known as the Digital Health and AI Zone. During the event, the company aims to engage in partnership meetings with global pharmaceutical and biotech firms and investors to seek new collaboration opportunities and enhance understanding of next-generation growth drivers.
The booth will feature the slogan "SK, AI for Every Patient," showcasing the comprehensive use of AI in drug discovery, digital transformation of R&D and operations, and patient-centered platforms.
SK Biopharm is expanding the application of its proprietary AI platform from research planning to candidate substance design and analysis, development strategy formulation, and operational optimization. The company envisions building an AI system that supports real-time collaboration and decision-making, moving beyond simple analysis. This approach is expected to reduce trial and error and allow for a focus on high-value research.
"We will expand global cooperation and strengthen our competitiveness in AI-based drug development," said Lee Dong-hoon, CEO of SK Biopharm.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.